Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease

Pais, Raluca; Rusu, Elena; Zilisteanu, Diana; Cîrciumaru, Alexandra; Micu, L.; Voiculescu, M; Poynard, Thierry; Ratziu, Vlad

doi:10.1016/j.ejim.2014.12.001

Cited by 44 publications

(41 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, according to the current reports [7,8,11,17,18,[103][104][105][106][107][108][109][110], the prevalence of NAFLD in CHB ranges widely from 13.6 to 59.3 % ( Table 1). The significant divergence may be due to the differences in ethnicity, demography, and the precise criterion in the studies.…”

Section: Clinical Study Prevalence and Causative Analysis Of Steatosimentioning

confidence: 85%

“…The results based on cell or animal models indicate that HBV may induce steatosis through a major panel of signaling pathways involved in the pathogenesis of NAFLD [13][14][15][16]. However, some other clinical studies argue that they are two independent diseases without pathologically promoting interactions underlying [7,9,11,[17][18][19]. In this review paper, we updated and analyzed the recent research progress and hot debates regarding this topic.…”

Section: Bmimentioning

confidence: 97%

“…With the dominance of over-rich diet and sedentary life style in modern society, as well as the growing prevalence of obesity and metabolic syndrome (MS), the incidence rate of NAFLD, currently varying from 6 to 35 %, keeps on increasing [5]; it is now becoming the most common liver disease in general population worldwide [6]. Meanwhile, the number of CHB patients with concomitant NAFLD increased gradually; the prevalence of NAFLD in the CHB patients may be more than 13 % [7,8]. As the pathogenesis processes of both CHB and NAFLD are getting clear and systematic, whether there can be any correlations between these two diseases attracts rising attention.…”

Section: Bmimentioning

confidence: 97%

“…Nevertheless, compared with the conditions of HCV infection, there are even more uncertainties regarding the pathogenic correlation between the HBV infection and NAFLD. Currently, some studies suggest that the major causative factors for HBV-associated hepatic steatosis are the host's own metabolic factors [7,9] or the genetic factors, such as patatin-like phospholipase domain-containing protein A3 (PNPLA3) polymorphism [48], but there are also some other reports considering the direct interactions of the HBV viral factors with the hepatic lipogenesis pathways [13,14,16,49,50]. Therefore, it has not been fully confirmed which factor holds the most prognostic value for the liver disease progression.…”

Section: Mechanistic Interactions Between Nafld and Hbv Infectionmentioning

confidence: 99%

See 3 more Smart Citations

Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact

et al. 2015

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is a major etiology of chronic liver disease worldwide. In the past decade, nonalcoholic fatty liver disease (NAFLD) has emerged as a common liver disorder in general population. Accordingly, the patient number of chronic hepatitis B (CHB) concomitant with NAFLD grows rapidly. The present article reviewed the recent studies aiming to explore the relationship between CHB and NAFLD from different aspects, including the relevant pathogenesis of CHB and NAFLD, the intracellular molecular mechanisms overlaying HBV infection and hepatic steatosis, and the observational studies with animal models and clinical cohorts for analyzing the coincidence of the two diseases. It is concluded that although numerous cross-links have been suggested between the molecular pathways in HBV infection and NAFLD pathogenesis, regarding whether HBV infection can substantially interfere with the occurrence of NAFLD or vice versa in the patients, there is still far from a conclusive agreement.

show abstract

Section: Clinical Study Prevalence and Causative Analysis Of Steatosimentioning

confidence: 85%

Section: Bmimentioning

confidence: 97%

Section: Bmimentioning

confidence: 97%

Section: Mechanistic Interactions Between Nafld and Hbv Infectionmentioning

confidence: 99%

See 2 more Smart Citations

Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact

et al. 2015

View full text Add to dashboard Cite

show abstract

“…An increase in patients who have CHB with concomitant NAFLD has been reported [6, 7]. Since the pathogenesis of CHB and NAFLD is complex, they may affect each other.…”

Section: Introductionmentioning

confidence: 99%

The Effect of Hepatosteatosis on Response to Antiviral Treatment in Patients with Chronic Hepatitis B: A Meta-Analysis

Zhu

Yang

et al. 2017

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Background. This study is to systematically analyze the effects of hepatosteatosis on the response to antiviral treatment in patients with chronic hepatitis B (CHB) and hepatosteatosis. Methods. Systematic search was performed in PubMed, Embase, Web of Science, Elsevier, and the Chinese BioMedical literature databases for relevant studies published until February 2016. Treatment outcomes were compared between patients with CHB plus concomitant hepatosteatosis and those without hepatosteatosis. Results. A total of 8 prospective cohort studies (399 patients with CHB plus hepatosteatosis and 688 patients with only CHB) were included. Biochemical and virological response at both 48 and 96 weeks were significantly lower in patients with CHB plus hepatosteatosis as compared to that in patients with only CHB. Subgroup analysis based on methods used for diagnosis of hepatosteatosis and treatment regimens showed that when hepatosteatosis was diagnosed on Doppler ultrasound and treated with nucleotide analogues, patients with CHB plus hepatosteatosis showed lower biochemical (62.7% versus 75.8%, P = 0.002) and virological response (66.2% versus 72.3%, P = 0.006) as compared to that in patients with CHB. Conclusion. Hepatosteatosis lowers the efficacy of antiviral treatment in patients with CHB, especially when hepatosteatosis was diagnosed on ultrasound findings and treated with nucleotide analogues.

show abstract

Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation

Brunt¹

2017

Hepatology Communications

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is one of the most common underlying causes of chronically elevated liver tests and liver disease in adults and children worldwide and may be strongly suspected if not diagnosed by ever evolving and available serologic and imaging‐based noninvasive tests. However, the definitive diagnosis of the most progressive form of NAFLD, nonalcoholic steatohepatitis, and the identification of fibrosis stage still require liver biopsy evaluation as noninvasive testing has not replaced some of the specifics or the totality of information obtainable from liver biopsy. In this review, both the role and value of a liver biopsy evaluation in NAFLD/ nonalcoholic steatohepatitis are examined from publications related to a selected variety of settings. Details of the most commonly used semiquantitative methods of analysis are discussed, and some useful potential pitfalls for differential diagnostic consideration in liver biopsy interpretation are given. (Hepatology Communications 2017;1:370–378)

show abstract

Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease

Cited by 44 publications

References 34 publications

Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact

Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact

The Effect of Hepatosteatosis on Response to Antiviral Treatment in Patients with Chronic Hepatitis B: A Meta-Analysis

Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation

Contact Info

Product

Resources

About